Treatment of non-small cell lung cancer - Where we are?;Leczenie zaawansowanego niedrobnokomórkowego raka płuca - W którym miejscu jesteśmy?

Pneumonologia i Alergologia Polska

Volumn 81, Issue 1, 2013, Pages 55-60

  Milanowski, Janusz ^a,b   Szmygin Milanowska, Katarzyna ^a  

^a Pracownia Immunologii i Genetyki Katedra i Klinika Pneumonologii Onkologii i Alergologii Uniwersytetu Medycznego W Lublinie   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer; Personalized therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; DISEASE FREE SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PATHOLOGY; POLAND; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; POLAND; QUALITY OF LIFE;

EID: 84871529184     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wojciechowska U., Didkowska J., Zatoński W. Nowotwory złośliwe w Polsce w 2008 roku. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa 2010.
2. Aberle D.R., Adams A.M., Berg C.D. i wsp. Baseline characteristics of participants in the randomized National Lung Screening Trial. J. Natl. Cancer Inst. 2010; 102: 1771-1779.
3. Rosell R., Gomez-Codina J., Camps C. i wsp. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 1994; 330: 153-158.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br. Med. J. 1995; 311: 899-909.
5. Lilenbaum R., Herndon J., List M. i wsp. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectivness (abstract). Proc. Am. Soc. Clin. Oncol. 2002; 21: 1a.
6. Schiller J.H., Harrington D., Belani C.P. i wsp. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002; 346: 92-98.
7. Greco A.F., Gray J.R., Thompson D.S. i wsp. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma. Cancer 2002; 95: 1279-1285.
8. Sandler A., Gray R., Perry M.C. i wsp. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006; 355: 2542-2550.
9. Manegold C., von Pawel J., Zatloukal P. i wsp. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapynaïve patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC): BO17704. Am. Soc. Clin. Oncol. Proc. 2007; abst. 7514].
10. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non small cell lung cancer: a systematic review and meta-analysis of individual patient data of 16 controlled clinical trials. J. Clin. Oncol. 2008; 26: 4617-4625.
11. Hanna N., Paul S., DeMarinis F. i wsp. O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41: 5-6.
12. Zheng Z., Chen T., Li X. i wsp. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 2007; 356: 800-808.
13. Langer C. J., Manola J., Bernardo P. i wsp. Cispaltin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. 2002; 94: 173-181.
14. Ciuleanu T., Brodowicz T., Zielinski C. i wsp. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
15. Paz-Ares L., de Marinis F., Dediu M. i wsp. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13: 247-255.
16. Cappuzzo F., Coudert B., Wierzbicki R. i wsp.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-529.
17. Zhou C., Wu Y.I., Chen G. i wsp. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. Ann. Oncol. 2010; 21 (supl. 8): (Abstr. LBA13).
18. Mok T.S., Wu Y.L., Thongprasert S. i wsp. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957.
19. Mitsudomi T., Morita S., Yatabe Y. i wsp. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
20. Shepherd F. A., Rodrigues Pereira J., Ciuleanu T. i wsp. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123-132.
21. Paez J.G., Janne P.A., Lee J.C. i wsp. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
22. Lynch T.J., Bell D.W., Sordella R. i wsp. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-2139.
23. Cappuzzo F., Hirsch F. R., Rossi E. i wsp. Epidermal Growth Factor Receptor (EGFR) and HER2 gene amplification predict response to gefitinib therapy in advanced non-small cell lung cancer (NSCLC) (abstrakt). Ann. Oncol. 2004; 15 (Supl. 3): 166.
24. Pirker R., Herth F.J., Kerr K.M. i wsp. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J. Thorac. Oncol. 2010; 5: 1706-1713.
25. Zhou C., Wu Y.I., Chen G. i wsp. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
26. Rosell R., Carcereny E., Gervais R. i wsp. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
27. Rosell R., Moran T., Queralt C i wsp. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361: 958-967.
28. Soda M., Choi Y.L., Enomoto M. i wsp. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
29. Kwak E.L., Bang Y.J., Camidge D.R. i wsp. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363: 1693-1703.
30. Shaw A.T., Yeap B.Y., Mino-Kenudson M. i wsp. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27: 4247-4253.
31. Perner S., Wagner P.L., Soltermann A. i wsp. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J. Pathol. 2009; 21: 65-72.
32. Spigel D.R., Ervin T.J., Ramlau R. i wsp. Final efficacy results from OAM4558g, a randomized phase II study evaluating Met-MAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 2011; 29: (supl.), abstr. 7505.
33. Hirsh V., Cadranel J., Cong J. i wsp. Symptom and Healthrelated Quality of Life Benefit of Afatinib (BIBW 2992) in Advanced NSCLC Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase III Trial (LUX-Lung 1). J. Thorac. Oncol. 2011; 6, (supl. 2), S324.
34. Temel J. S., Greer J. A., Muzikansky A. i wsp. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 2010; 363: 733-742.